An interventional study of Pistachio Co-consumption and Refined-Carbohydrate Control Co-consumption in Obesity / Overweight, sponsored by St. Louis University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by St. Louis University · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled crossover study will examine the acute effects of pistachio consumption on postprandial metabolic responses in adults with overweight or obesity. Participants will complete two experimental conditions in randomized order. In one condition, participants will consume 30 g of pistachios with a standardized meal, and in the other condition they will receive an isocaloric refined-carbohydrate control condition with the standardized meal.
The study will evaluate postprandial insulin and glucose responses over approximately 3 hours after meal consumption. Additional outcomes will include continuous glucose monitoring measures, blood lipid responses, appetite and satiety ratings, and exploratory measures related to insulin sensitivity and gastrointestinal hormone responses. The study is designed to determine whether pistachio consumption alters acute metabolic responses compared with an isocaloric refined-carbohydrate control in adults with overweight or obesity.
This study is a randomized, controlled, crossover feeding trial designed to investigate the acute effects of pistachio consumption on postprandial metabolic responses in adults with overweight or obesity. Each participant will complete both experimental conditions in randomized order, thereby serving as their own control. Experimental visits will be separated by a washout period.
After an overnight fast, participants will receive either 30 g of pistachios or an isocaloric refined-carbohydrate control with a standardized meal. Serial blood samples will be collected during the postprandial period to assess insulin and glucose responses. The primary metabolic outcome will focus on the postprandial insulin response over the 0- to 180-minute period.
Additional outcomes will characterize postprandial glucose responses, including measures obtained using continuous glucose monitoring, as well as appetite and satiety ratings and blood lipid responses. Exploratory analyses may include indices of insulin sensitivity and resistance and gastrointestinal hormones involved in metabolic regulation. The crossover design will allow direct within-participant comparison of the pistachio and control conditions.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 28 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →St. Louis University is the lead sponsor of 156 studies on the registry; 17 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this sequence will first complete the pistachio condition, in which 30 g of shelled pistachios are consumed with the standardized high-glycemic breakfast meal. After a 3-7 day washout period, participants will complete the refined-carbohydrate control condition, in which an isocaloric refined-carbohydrate control food is consumed with the same standardized breakfast meal.
Other: Pistachio Co-consumption · Other: Refined-Carbohydrate Control Co-consumption
Participants randomized to this sequence will first complete the refined-carbohydrate control condition, in which an isocaloric refined-carbohydrate control food is consumed with the standardized high-glycemic breakfast meal. After a 3-7 day washout period, participants will complete the pistachio condition, in which 30 g of shelled pistachios are consumed with the same standardized breakfast meal.
Other: Pistachio Co-consumption · Other: Refined-Carbohydrate Control Co-consumption
Participants will consume 30 g of shelled, lightly salted pistachios together with a standardized high-glycemic breakfast meal. The pistachios and standardized breakfast meal will be consumed within a fixed 10-minute meal period.
Participants will consume an isocaloric refined-carbohydrate control food together with the same standardized high-glycemic breakfast meal. The control food will be matched to the pistachio condition for energy content as closely as possible while providing minimal fiber, protein, unsaturated fat, and bioactive compounds.
Postprandial Insulin Incremental Area Under the Curve (iAUC)
Postprandial plasma insulin will be measured at 0, 30, 60, 90, 120, 150, and 180 minutes after meal consumption. Insulin incremental area under the curve (iAUC) from 0 to 180 minutes will be calculated using the trapezoidal rule with baseline subtraction. Insulin iAUC will be compared between the pistachio and refined-carbohydrate control conditions.
Time frame: 0-180 minutes after meal consumption
Postprandial Plasma Glucose Incremental Area Under the Curve (iAUC)
Plasma glucose concentrations will be measured at 0, 30, 60, 90, 120, 150, and 180 minutes after meal consumption. Glucose iAUC from 0 to 180 minutes will be calculated using the trapezoidal rule with baseline subtraction and compared between conditions.
Time frame: 0-180 minutes after meal consumption
Continuous Glucose Monitoring Time in Range
Percentage of CGM glucose readings within the predefined range of 70-180 mg/dL during the postprandial laboratory monitoring period will be calculated and compared between the pistachio and refined-carbohydrate control conditions.
Time frame: 0-180 minutes after meal consumption
Continuous Glucose Monitoring Mean Glucose
Mean interstitial glucose concentration measured by continuous glucose monitoring during the postprandial laboratory monitoring period will be calculated and compared between conditions.
Time frame: 0-180 minutes after meal consumption
Continuous Glucose Monitoring Glycemic Variability
Glycemic variability will be assessed using the coefficient of variation (CV) of CGM-derived interstitial glucose concentrations during the postprandial monitoring period and compared between conditions.
Time frame: 0-180 minutes after meal consumption
Continuous Glucose Monitoring Peak Glucose
The highest interstitial glucose concentration recorded by continuous glucose monitoring during the postprandial monitoring period will be determined and compared between conditions.
Time frame: 0-180 minutes after meal consumption
Continuous Glucose Monitoring Time to Peak Glucose
Time from meal consumption to the highest CGM-derived interstitial glucose concentration during the postprandial monitoring period will be determined and compared between conditions.
Time frame: 0-180 minutes after meal consumption
Postprandial Hunger Rating
Self-reported hunger will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.
Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption
Postprandial Fullness Rating
Self-reported fullness will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.
Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption
Postprandial Satisfaction Rating
Self-reported satisfaction will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.
Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption
Postprandial Desire to Eat Rating
Self-reported desire to eat will be assessed using a 100-mm visual analog scale (VAS) at baseline and 30, 60, 120, and 180 minutes after meal consumption and compared between conditions.
Time frame: Baseline and 30, 60, 120, and 180 minutes after meal consumption
Postprandial Plasma Triglycerides
Plasma triglyceride concentrations will be assessed before and after the test meal to evaluate the acute postprandial lipid response and compared between the pistachio and refined-carbohydrate control conditions.
Time frame: Baseline and 180 minutes after meal consumption
Postprandial Glucagon-Like Peptide-1 (GLP-1) Concentrations
GLP-1 concentrations will be assessed from stored plasma samples to explore the acute incretin response to the pistachio and refined-carbohydrate control conditions, if funding and sample availability permit.
Time frame: During the 0-180-minute postprandial period
Postprandial Glucose-Dependent Insulinotropic Polypeptide (GIP) Concentrations
GIP concentrations will be assessed from stored plasma samples to explore the acute incretin response to the pistachio and refined-carbohydrate control conditions, if funding and sample availability permit.
Time frame: During the 0-180-minute postprandial period
Plan to share: No — Individual participant data are not currently planned to be shared with researchers outside the study team. Study results will be reported in aggregate or de-identified form in accordance with applicable institutional, ethical, and privacy requirements.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 9 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.